Regentis Biomaterials (NYSE American: RGNT) has announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. The product aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
The announcement underscores Regentis’ commitment to bringing GelrinC to European patients and surgeons. By initiating training at a renowned institution like Humanitas Research Hospital, the company is positioning itself to build a strong foundation for clinical adoption. The Centers of Excellence network will further support this effort by providing ongoing education and best practices. For more details, the full press release is available at https://ibn.fm/QOWWK.
Forward-looking statements in this article involve risks and uncertainties, including those described in the company’s filings with the SEC. Investors should not place undue reliance on these statements, which are based on information available as of the date hereof. Regentis undertakes no duty to update this information unless required by law.
